Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

Phase II data from study of GAMMAGARD-treated patients announced at the

American Academy of Neurology annual meeting

CHICAGO, April 17 /PRNewswire-FirstCall/ -- New York-Presbyterian Hospital/Weill Cornell Medical Center and Baxter International Inc. (NYSE: BAX) announced results of a six-month, placebo-controlled Phase II study of 24 patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)] for the treatment of mild-to-moderate Alzheimer's disease today at the American Academy of Neurology (AAN) annual meeting in Chicago. The study met the primary endpoint criteria favoring GAMMAGARD LIQUID and GAMMAGARD S/D over placebo on measures of cognitive function and global impression of change, which are common measures of outcome in Alzheimer's disease clinical trials. The study also met secondary endpoints that measured changes in beta-amyloid and anti-amyloid antibody levels in blood and cerebrospinal fluid. Results show findings indicative of potential efficacy and tolerability. Key findings throughout six months included: measurements of clinical outcome, behavioral outcome and cognitive performance in Alzheimer's patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID compared to placebo. Twelve-to-18 month data will be available later this year.

Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have increased in the blood and cerebrospinal fluid of patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID, while the levels of beta-amyloid increased in the blood. Beta-amyloid is a substance thought to contribute to the degeneration of the brain in Alzheimer's disease. Clearing this substance from the central nervous system, therefore is hypothesized to help remove or reduce the building blocks of Alzheimer's.

The primary and secondary endpoint data were reported by the lead researcher for the trial, Dr. Norman Relkin, director of the Memory
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Ala. , Aug. 27, 2015 /PRNewswire/ ... Outpatient Pharmacy Provider (IOPP™) is expanding its ... of a medication-focused transition of care program ... named "RxCare Management," provides hospitals with technology ... hospital performance measures that have been mandated ...
(Date:8/27/2015)... , Aug. 27, 2015  A mere one ... Booz Allen Hamilton . A new white ... development inefficiencies are impeding and disrupting manufacturers, success. ... Waste and Improve Value In Product Development Processes ... inaccessible data and how it affects the product development ...
(Date:8/27/2015)... NorthStar Anesthesia , one of the country,s ... selected by Mercy, based in Toledo, Ohio ... hospitals:  Mercy St. Vincent  Medical Center and Mercy St. ... St. Charles  Hospital in Oregon and ... "As we looked to create a more ...
Breaking Medicine Technology:Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2
... CYBX ), a global leader in epilepsy management, today ... Sciences Conference on Wednesday, September 21, 2011, in New York. ... will speak to the attendees of the conference 10:00 AM ... be accessed by clicking on the Investor Relations link on ...
... 7, 2011 Generex Biotechnology Corporation ( www.generex.com ... the Company,s President & Chief Executive Officer, and ... wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ) ... & Renshaw 13th Annual Healthcare Conference.  The presentation ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, making ... Insurance is sharing some tips to help your whole family travel safely and comfortably. ... with pets each year. Amica is sharing the following tips from the American Society ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Analysis signed a partnership agreement for quality market research promotion on the ... by Black Swan Analysis. , Commenting on the partnership agreement, Natalie Aster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its ... grown to having twelve offices in three counties, LA, Orange and San Bernardino. ... California region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope ...
Breaking Medicine News(10 mins):Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... patients with the help of seroquel is effective//, ... chronic severe disabling mental illness. Some of the ... heard, feelings of being persecuted, becoming withdrawn, and ... only one in five patients have a chance ...
... diabetes drug thiazolidinediones (TZDs) can cause //edema. ,Scientists from ... activates a receptor in kidney called peroxisome proliferator-activated receptor gamma ... kidney. The activation of the receptor serves to retain the ... are generally used to lower blood sugar levels and lipid ...
... increase the risk of the Alzheimer’s disease// if people ... to a research study that is presented in the ... held in US, periodontal conditions could affect the incidence ... the brain cells and slowly destroys them. The main ...
... friendship that can keep people have a long life//. ... of having friends do affect the health and emotional well ... get significantly increased. ,The researchers had surveyed about ... the phone for about ten years in the age group ...
... had licensed the use of strontium ranelate to be used ... prescribing the drug it is important to observe the changes ... British Medical Journal has said that the drug strontium ranelate ... that this effect can be used in advantage of the ...
... have shown that consumption of trans fatty acids ... disease. Trans fatty acids are the hydrogenated and ... baked goods and many processed foods. They are ... in the presence of metal catalysts and in ...
Cached Medicine News:
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... can operate in two additional modes. The ... creating a fully featured handheld pulse oximeter, ... used to upgrade existing equipment through the ... or software upgrades to improve the performance ...
... The stylish Avant® 9600s simple functionality, ... of memory makes it well-suited for ... proven digital pulse oximetry, the Avant ... rugged durability. The 9600 provides a ...
Medicine Products: